	C 2012 Mar 31	2013 Mar 31	2014 Mar 31	2015 Mar 31	2016 Mar 31	R 2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M PRESS
Total Revenue	532	390	474	517	564	544	571	728	832	814	806	1,003	1,296	1,716	2,276
Cost of Operating Revenue	208	190	199	233	240	226	247	293	361	358	383	447	693	1,046	1,409
Gross Profit	324	200	275	284	324	318	324	435	471	456	423	556	602	670	866
Gross Margin	60.9	51.2	58.0	54.9	57.4	58.5	56.8	59.8	56.6	56.0	52.5	55.4	46.5	39.1	38.1
Total Operating Expenses	508	471	497	544	564	522	537	672	729	698	736	854	1,124	1,501	2,042
Operating Profit	23	-81	-23	-27	-1	22	34	56	103	116	69	149	171	215	233
Operating Margin	4.4	-20.7	-4.9	-5.2	-0.1	4.0	6.0	7.7	12.3	14.2	8.6	14.8	13.2	12.5	10.3
Financing Income/(Expense) - Net	5	3	6	5	5	6	11	16	11	9	10	23	31	30	-4
Profit before Taxes	29	-70	-	-21	6	36	44	73	114	127	83	134	220	156	252
Income Taxes	9	19	1	-	1	15	18	18	42	34	21	35	58	41	65
Profit after Tax	20	-90	-1	-21	5	20	26	54	72	93	62	99	162	116	188
PAT Margin	3.7	-22.9	-0.1	-4.0	0.9	3.7	4.5	7.5	8.7	11.5	7.6	9.9	12.5	6.7	8.2
EPS - Basic - ex Extraordinary Items	7.91	-35.81	-0.20	-8.34	2.10	8.02	10.36	21.78	28.88	37.32	24.64	39.72	64.60	46.30	75.01
EPS - Diluted - ex Extraordinary Items	7.91	-35.81	-0.20	-8.34	2.10	8.02	10.36	21.78	28.88	37.32	24.64	39.72	64.60	46.30	75.01
EBIT	23	-81	-23	-27	-1	22	34	56	103	116	69	149	171	215	233
EBITDA	31	-68	-13	-11	17	37	49	71	121	136	86	165	186	255	262
EBITDA Margin	5.7	-17.5	-2.7	-2.2	3.0	6.9	8.6	9.8	14.6	16.7	10.7	16.5	14.4	14.8	11.5

Balance Sheet

Abridged

Understanding Balance Sheet

Astrazeneca Pharma India Ltd. balance sheet covering assets, liabilities, equity and borrowings across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	R 2012 Mar 31	2013 Mar 31	C 2014 Mar 31	2015 Mar 31	R 2016 Mar 31	R 2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Source:	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	PRESS
Total Current Assets	195	165	275	263	266	252	321	405	542	619	706	835	933	1,342	1,732
Long-Term Investments	0	0	0	0	0	-	-	-	-	-	3	3	-	3	13
Property Plant & Equipment - Net	90	98	104	113	104	92	79	82	96	85	77	70	65	64	117
Total Non-Current Assets	150	141	141	148	183	164	140	157	164	156	151	149	145	176	257
Total Assets	345	306	416	412	449	415	461	562	706	775	857	985	1,078	1,518	1,989
Total Current Liabilities	155	206	244	260	243	190	207	259	327	304	333	384	357	703	982
Long Term Debt	-	-	-	-	-	-	-	-	9	9	5	4	3	29	97
Total Non-Current Liabilities	1	0	0	1	2	2	7	2	15	15	13	12	9	45	135
Total Liabilities	156	206	244	261	245	193	214	261	342	319	345	396	366	748	1,116
Total Shareholders' Equity	189	100	172	151	203	223	247	301	364	456	511	589	712	770	873
Total Equity	189	100	172	151	203	223	247	301	364	456	511	589	712	770	873
Total Liabilities & Equity	345	306	416	412	449	415	461	562	706	775	857	985	1,078	1,518	1,989

Cash Flow

Abridged

Understanding Cash Flow Statement

Astrazeneca Pharma India Ltd. cash flow statement covering operating, investing and financing activities across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	C 2012 Mar 31	2013 Mar 31	2014 Mar 31	2015 Mar 31	2016 Mar 31	R 2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M PRESS
Operating CF bef Changes in Working Cap	5.40	-64.35	-14.71	-8.20	20.18	44.00	51.01	56.19	100.87	116.96	78.07	111.00	187.61	198.96	219.78
Working Capital - Increase/(Decrease)	38.58	61.23	17.66	-32.58	42.09	-0.24	-34.25	9.81	-2.66	-3.95	32.89	-30.19	-128.17	-103.22	-217.38
Net CF from Operating Activities	43.98	-3.12	2.95	-40.78	62.28	43.76	16.76	66.00	98.21	113.01	110.96	80.81	59.44	95.74	2.40
Capital Expenditures - Net	38.94	18.53	18.33	23.57	8.92	5.42	6.25	18.42	13.73	5.29	6.37	5.04	10.35	1.04	3.34
Net CF from Investing Activities	-38.94	-18.53	-18.33	-23.57	-8.92	-5.41	-17.33	-6.74	-182.73	163.71	-6.37	-5.04	-10.35	-1.04	-3.34
Dividends Paid - Cash - Total	24.96	8.91	-	-	-	-	-	-	2.50	5.00	5.00	20.00	40.00	60.00	80.00
Debt - LT & ST - Issuance/(Retirement) - Total	-0.05	-	-0.02	-	-0.28	-	-	-	-2.21	-2.88	-3.51	-3.85	-3.86	-4.13	-7.48
Net Cash Flow from Financing Activities	-29.07	-10.33	86.22	-	-0.49	-	-	-	-5.22	-7.88	-8.51	-23.85	-43.86	-64.13	-87.48
Free Cash Flow to Equity	4.99	-21.65	-15.40	-64.34	53.09	38.34	10.51	47.58	82.27	104.84	101.08	71.92	45.23	90.57	-8.42
Free Operating CF net dividend	-20.83	-30.82	-18.69	-64.58	53.23	38.11	10.48	47.31	81.49	100.30	96.34	52.29	8.68	33.99	-81.21
Free Operating CF	4.13	-21.91	-18.69	-64.58	53.23	38.11	10.48	47.31	83.99	105.30	101.34	72.29	48.68	93.99	-1.21

Business Segment Analysis

FY End:

Mar 25

Astrazeneca Pharma India Ltd. business segment breakdown covering revenue, operating income and assets across key divisions for the selected financial year.

Capex

Healthcare (100.0%)₹ 1.75 Cr

Revenue / Sales

Healthcare (100.0%)₹ 1,716.29 Cr

Assets

Healthcare (100.0%)₹ 1,518.12 Cr

Operating Income

Healthcare (100.0%)₹ 214.81 Cr

Regional Segment Analysis

FY End:

Mar 25

Astrazeneca Pharma India Ltd. geographic revenue split showing domestic and international market performance across revenue and income for the selected financial year.

Revenue / Sales

India (93.6%)₹ 1,606.60 CrOutside India (6.4%)₹ 109.69 Cr

Historical Segment Analysis

Track how Astrazeneca Pharma India Ltd. segment contributions have evolved over multiple financial years to see which divisions are growing, shrinking or gaining strategic importance.

Capex

Sales

Assets

Operating Income

Business

Regional

Business

	2012 Mar 31	2013 Mar 31	2014 Mar 31	2015 Mar 31	2016 Mar 31	2017 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31

Healthcare	46	21	16	25	8	4	14	8	10	9	11	2
Others	0	0	0	0	0	0	-	-	-	-	-	-

Frequently Asked Questions

What is the revenue of Astrazeneca Pharma India Ltd.?

The latest trailing twelve month revenue of Astrazeneca Pharma India Ltd. is ₹ 2,275.58 Cr, reflecting a 1-year growth of 32.59% and a 3-year CAGR of 31.40%. Annual and quarterly revenue trends are available in the Income Statement section.

What is the net profit of Astrazeneca Pharma India Ltd.?

The latest trailing twelve month net profit (PAT) of Astrazeneca Pharma India Ltd. is ₹ 187.52 Cr, with a 3-year earnings CAGR of 23.61%. Detailed profit history across annual and quarterly periods is in the Income Statement section.

What is the EBITDA of Astrazeneca Pharma India Ltd.?

The trailing twelve month EBITDA of Astrazeneca Pharma India Ltd. is approximately ₹ 233.45 Cr (based on an operating margin of 10.26%). EBITDA reflects core operating profitability before interest, taxes, depreciation and amortisation.

What is the EPS of Astrazeneca Pharma India Ltd.?

The trailing twelve month Earnings Per Share (EPS) of Astrazeneca Pharma India Ltd. is 75.01. EPS trends across annual and quarterly periods are visible in the Income Statement section.

What is the debt level of Astrazeneca Pharma India Ltd.?

The debt-to-equity ratio of Astrazeneca Pharma India Ltd. stands at 0.13. The interest coverage ratio is 51.99x, reflecting the company's ability to service debt from operating earnings. The full breakdown of total borrowings is in the Balance Sheet section.

What is the book value per share of Astrazeneca Pharma India Ltd.?

The estimated book value per share of Astrazeneca Pharma India Ltd. is 349.12 (derived from a P/B ratio of 23.28 and market price of ₹ 8,126.00), reflecting the net asset value attributable to each share. See the Balance Sheet section for a full breakdown.

What is the cash flow from operations of Astrazeneca Pharma India Ltd.?

The trailing twelve month operating cash flow of Astrazeneca Pharma India Ltd. is ₹ 2.40 Cr. Annual and quarterly cash flow data is available in the Cash Flow section of the Statements tab.

Does Astrazeneca Pharma India Ltd. report consolidated or standalone financials?

Astrazeneca Pharma India Ltd. reports consolidated financials. You can toggle between consolidated and standalone views using the switch at the top of each statement section.